Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Cancer Therapeutics

Background:

• Squamous cell anal carcinoma (SCAC) lacks standard chemotherapeutic options for patients with relapsed or progressive disease after cisplatin-based regimens.
• Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are a potential therapeutic strategy for various malignancies.

Observation:

• This report details a patient with SCAC who experienced disease progression on standard palliative chemotherapy.
• The patient's tumor was profiled for molecular targets.

Findings:

• The patient received a combination therapy of irinotecan and cetuximab, an EGFR-targeting monoclonal antibody.
• This combination therapy resulted in a beneficial outcome for the patient, suggesting a potential treatment avenue.

Implications:

• This case highlights the potential benefit of molecular profiling to guide treatment decisions in SCAC.
• The combination of irinotecan and cetuximab may represent a viable therapeutic option for select patients with advanced SCAC.
• Further research is warranted to explore the efficacy of EGFR-targeted therapies in squamous cell anal carcinoma.